CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. Between 74-89% of retail investor accounts lose money when trading CFDs. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money. Please refer to our Risk Disclosure Statement
Open platformOpen platform

Moderna’s Bundibugyo Ebola Vaccine Gets Recommendation for Phase 2/3 Trial

By Public Technologies
  • Moderna’s investigational Bundibugyo ebolavirus vaccine, mRNA-1469, was recommended to advance into the Phase 2/3 Tumaini efficacy trial in the Democratic Republic of Congo.
  • The recommendation followed a WHO advisory group’s October 22 review; trial participation remains subject to regulatory approval.
  • Reported interim Phase 1 results showed the vaccine was generally well tolerated, with a single dose generating strong virus-specific antibody responses.
  • CEPI has committed up to US$58.5 million for vaccine development and trial-dose manufacturing, with separate funding for Tumaini.
  • No vaccine is currently licensed specifically to prevent Bundibugyo virus disease.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Moderna Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 202611041105ACCESSWRNAPR_____1246308) on November 04, 2026, and is solely responsible for the information contained therein.

Capital Com is an execution-only service provider. The present material must be regarded as marketing communication and should not be interpreted as investment research or investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page, then you do so entirely at your own risk